All In Biotech

Drug Trial Radar · NCT05976685

Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy

Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic StrokE Despite Anticoagulation Therapy

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 482 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

482

Planned (sponsor's estimate)

Start

May 1, 2024

Primary completion

Jan 1, 2028

Study completion Jun 1, 2028

Sponsor

Lead sponsor
Insel Gruppe AG, University Hospital BernAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 4, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Atrial fibrillation (AF) is one of the most common cardiac arrhythmias and cardioembolic stroke due to AF is its major complication. Direct oral anticoagulants (DOAC) reduce the risk of cardioembolism in patients with AF. Despite DOAC therapy, there is a significant residual stroke risk of 1-2%/year. Recent data from the Swiss Stroke Registry found 38% of patients with AF and ischemic stroke were on prior anticoagulant therapy (approximately 400 patients per year in Switzerland). The investigators found in a prior observational study, that patients with AF who have ischemic stroke despite anticoagulation are at increased risk of having another ischemic stroke (HR 1.6; 95% confidence interval, CI 1.1-2.1). Combining observational data from 11 international stroke centres, the investigators found that the majority of ischemic strokes despite anticoagulation in patients with AF is "breakthrough" cardioembolism (76% of patients) and only a minority of 24% is related to other causes unrelated to AF. Optimal secondary prevention strategy is unknown. The investigators have conducted two independent observational studies including together \>4000 patients but did not identify any strategy (e.g. switch to different DOAC, additional antiplatelet therapy) that seems superior. A recent randomized controlled trial on surgical occlusion of the left atrial appendage (LAAO) found that LAAO may provide additional protection from ischaemic stroke in addition to oral anticoagulation. Triggered by this finding, the investigators performed a matched retrospective observational study and found that patients with AF and stroke despite anticoagulation who received a combined mechanical-pharmacological therapy (DOAC therapy + LAAO) had lower rates of adverse outcomes compared to those with DOAC therapy alone. Therefore, the investigators hypothesize that in patients with AF and ischemic stroke despite anticoagulant therapy, LAAO in addition to anticoagulation with a DOAC is superior to DOAC therapy alone. The investigators propose an international, multi-center randomized controlled two-arm trial to assess the effect of LAAO in patients with AF suffering from strokes despite anticoagulation therapy and without competing stroke etiology. The investigators will use the PROBE design with blinded endpoint assessment. The investigators will enrol patients with non-valvular AF and a recent ischemic stroke despite anticoagulation therapy at stroke onset. Patients will be randomized 1:1 to receive LAAO + DOAC therapy (experimental arm) or DOAC therapy alone (standard treatment arm). The primary endpoint is the first occurrence of a composite outcome of recurrent ischemic stroke, systemic embolism and cardiovascular death during follow-up. Secondary outcomes include individual components of the primary composite outcome, safety outcomes (i.e. symptomatic intracranial haemorrhage, major extracranial bleeding, serious device- or procedure-related complication), functional outcome (modified Rankin Scale) and patient-oriented outcomes. The minimum follow-up is 6 months and all patients will receive follow-ups every 6 months until end of study, the maximal follow-up will be 48 months. Based on prior observational data from the investigators' group and others (5 observational studies, \>5000 patients), the investigators estimate the proportion of patients with the primary outcome in the standard treatment arm to be 18% in the first year and 9% in the second year (=cumulative 27% after 2 years). A relative risk reduction of 40% at 2 years would be clinically relevant. Based on these assumptions and a log-rank test, the investigators would need 98 events for a power of 80% at an alpha-level of 5%. Assuming a recruitment rate of 52, 118, 156 and 156 patients in years 1 to 4, an additional 6 months of follow-up (mean follow-up time of 2.1 years) and a uniform drop-out rate of 7.5% per year, 482 patients would need to be enrolled. How to treat patients with an ischemic stroke despite anticoagulation is a major yet unresolved clinical dilemma. This trial has the potential to answer the question whether LAAO plus DOAC therapy is superior to current standard of care for patients with AF who have ischemic stroke despite anticoagulation.

Conditions

  • Ischemic Stroke
  • Atrial Fibrillation

Interventions

  • Left atrial appendage OcclusionProcedure

    Left atrial appendage Occlusion and therapy with direct oral anticoagulants. Choice of DOAC is at the discretion of the treating physician.

  • DOACDrug

    Therapy with direct oral anticoagulants. Choice of DOAC is at the discretion of the treating physician.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite of recurrent ischemic stroke, systemic embolism, or cardiovascular death (whatever comes first).Time frame: 6 months

Locations

35 sites in 6 countries. Site status is shown where the registry gives one.

  • AZ Sint Jan Brugge

    Bruges, Belgium · Recruiting

  • Brussels University Hospital

    Brussels, Belgium · Recruiting

  • UCLouvain - Cliniques universitaires Saint-Luc

    Brussels, Belgium · Recruiting

  • HUmani CHU Charleroi-Chimay

    Charleroi, Belgium · Recruiting

  • Universitair Ziekenhuis (UZ) Leuven

    Leuven, Belgium · Recruiting

  • CHU Liège Sart-Tilman

    Liège, Belgium · Recruiting

  • Charité-Universitätsmedizin Berlin

    Berlin, Germany · Recruiting

  • Universitätsklinikum Bonn

    Bonn, Germany · Recruiting

  • Universitätsmedizin Göttingen

    Göttingen, Germany · Recruiting

  • Asklepios Klinik Altona

    Hamburg, Germany · Recruiting

  • University Hospital Heidelberg

    Heidelberg, Germany · Recruiting

  • Universitätsklinikum Leipzig

    Leipzig, Germany · Recruiting

  • Universitätsmedizin Mannheim

    Mannheim, Germany · Recruiting

  • Universitätsklinikum Tübingen

    Tübingen, Germany · Recruiting

  • UKSH, Campus Lübeck

    Lübeck, Schleswig-Holstein, Germany · Recruiting

  • Christchurch Hospital

    Christchurch, New Zealand · Recruiting

  • Hosp. General Universario Dr. Balmis de Alicante

    Alicante, Spain · Recruiting

  • Hospital del Mar

    Barcelona, Spain · Recruiting

  • Hosp. Barcelona Santa Creu y Sant Pau

    Barcelona, Spain · Recruiting

  • Vall d'Hebron University Hospital

    Barcelona, Spain · Recruiting

  • Hosp. Clínic of Barcelona

    Barcelona, Spain · Recruiting

  • Hospital Clínico San Carlos (HCSC)

    Madrid, Spain · Recruiting

  • University Hospital Basel

    Basel, Switzerland · Recruiting

  • Inselspital, University Hospital Bern

    Bern, Switzerland · Recruiting

  • Hôpitaux universitaires de Genève

    Geneva, Switzerland · Not yet recruiting

  • Luzerner Kantonsspital

    Lucerne, Switzerland · Not yet recruiting

  • Kantonsspital St. Gallen

    Sankt Gallen, Switzerland · Recruiting

  • Stadtspital Zürich Triemli

    Zurich, Switzerland · Recruiting

  • Ente Ospedaliero Cantonale

    Lugano, Canton Ticino, Switzerland · Recruiting

  • Centre Hospitalier Universitaire Vaudois

    Lausanne, Vaude, Switzerland · Recruiting

  • Addenbrooke's Hospital

    Cambridge, United Kingdom · Recruiting

  • Charing Cross Hospital

    London, United Kingdom · Recruiting

  • St Bartholomew's Hospital

    London, United Kingdom · Recruiting

  • St Thomas' Hospital

    London, United Kingdom · Recruiting

  • University Hospitals Sessex NHS Trust

    Worthing, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.